CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:CYTR
- CUSIP: N/A
- Web: www.cytrx.com
Capitalization:- Market Cap: $73.97 million
- Outstanding Shares: 165,710,000
Average Prices:- 50 Day Moving Avg: $0.56
- 200 Day Moving Avg: $0.55
- 52 Week Range: $0.36 - $1.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.05
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $100,000.00
- Price / Sales: 715.87
- Book Value: $0.13 per share
- Price / Book: 3.46
Profitability:- EBIDTA: ($41,940,000.00)
- Return on Equity: -222.67%
- Return on Assets: -74.07%
Debt:- Debt-to-Equity Ratio: 0.82%
- Current Ratio: 2.44%
- Quick Ratio: 2.44%
Misc:- Average Volume: 5.77 million shs.
- Beta: 2.55
- Short Ratio: 2.28
Frequently Asked Questions for CytRx Corporation (NASDAQ:CYTR)
What is CytRx Corporation's stock symbol?
CytRx Corporation trades on the NASDAQ under the ticker symbol "CYTR."
How were CytRx Corporation's earnings last quarter?
When will CytRx Corporation make its next earnings announcement?
Where is CytRx Corporation's stock going? Where will CytRx Corporation's stock price be in 2017?
3 analysts have issued 1-year price targets for CytRx Corporation's shares. Their forecasts range from $3.00 to $4.00. On average, they expect CytRx Corporation's stock price to reach $3.50 in the next year. View Analyst Ratings for CytRx Corporation.
Who are some of CytRx Corporation's key competitors?
Some companies that are related to CytRx Corporation include Pluristem Therapeutics (PSTI), Regulus Therapeutics (RGLS), CTI BioPharma Corp. (CTIC), GTx (GTXI), Novelion Therapeutics (NVLN), Oramed Pharmaceuticals (ORMP), Silence Therapeutics plc (SLN), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), CASI Pharmaceuticals (CASI), aTyr Pharma (LIFE), Palatin Technologies (PTN), Tissue Regenix Group PLC (TRX), Eiger Biopharmaceuticals (EIGR), Zynerba Pharmaceuticals (ZYNE), ArQule (ARQL), Vernalis plc (VER) and Brainstorm Cell Therapeutics (BCLI).
Who are CytRx Corporation's key executives?
CytRx Corporation's management team includes the folowing people:
- John Y Caloz, Chief Financial Officer
- David J. Haen, Vice President - Business Development
- Shanta Chawla M.D., Senior Executive Officer - Drug Development
- Olivia C. Ware, Chief Commercial Officer
- Steven A. Kriegsman, Chairman of the Board, President, Chief Executive Officer
- Earl W. Brien M.D., Director
- Joel Caldwell, Director
- Louis J. Ignarro Ph.D., Independent Director
Who owns CytRx Corporation stock?
CytRx Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.17%), Goldman Sachs Group Inc. (0.42%), LMR Partners LLP (0.25%) and Northern Trust Corp (0.16%). View Institutional Ownership Trends for CytRx Corporation.
Who sold CytRx Corporation stock? Who is selling CytRx Corporation stock?
Who bought CytRx Corporation stock? Who is buying CytRx Corporation stock?
How do I buy CytRx Corporation stock?
Shares of CytRx Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytRx Corporation's stock price today?
One share of CytRx Corporation stock can currently be purchased for approximately $0.43.
MarketBeat Community Rating for CytRx Corporation (NASDAQ CYTR)MarketBeat's community ratings are surveys of what our community members think about CytRx Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for CytRx Corporation (NASDAQ:CYTR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $3.50 (710.19% upside) |
Analysts' Ratings History for CytRx Corporation (NASDAQ:CYTR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/26/2017 | HC Wainwright | Reiterated Rating | Buy | $4.00 | High |  |
| 3/21/2017 | Aegis | Reiterated Rating | Buy | | Medium | |
| 11/14/2016 | FBR & Co | Set Price Target | Buy | $3.00 | N/A | |
| 7/15/2016 | Jefferies Group LLC | Reiterated Rating | Hold | $2.50 -> $0.75 | N/A | |
| 7/12/2016 | S&P Equity Research | Lower Price Target | | $1.04 -> $0.75 | N/A | |
| 11/6/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $10.00 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for CytRx Corporation (NASDAQ:CYTR)Earnings History by Quarter for CytRx Corporation (NASDAQ CYTR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | | | | | | N/A | |
| 5/10/2017 | Q1 2017 | | ($0.10) | | | View | N/A | |
| 7/29/2016 | Q2 | ($0.19) | ($0.27) | | $0.10 million | View | N/A | |
| 5/11/2016 | Q116 | ($0.26) | ($0.19) | | | View | N/A | |
| 11/3/2015 | Q315 | ($0.24) | ($0.17) | | | View | N/A | |
| 8/3/2015 | Q215 | ($0.27) | ($0.25) | | | View | N/A | |
| 5/1/2015 | Q115 | ($0.21) | ($0.28) | | | View | N/A | |
| 3/10/2015 | Q4 2014 | ($0.27) | ($0.24) | | $0.10 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.25) | ($0.10) | | | View | N/A | |
| 8/6/2014 | Q214 | ($0.20) | ($0.28) | | | View | N/A | |
| 3/5/2014 | | ($0.17) | ($0.25) | | $0.10 million | View | N/A | |
| 10/29/2013 | Q313 | ($0.22) | ($0.33) | $0.20 million | | View | N/A | |
| 8/6/2013 | Q2 2013 | ($0.19) | ($0.11) | | | View | N/A | |
| 5/9/2013 | Q113 | ($0.15) | ($0.23) | | | View | N/A | |
| 3/11/2013 | Q4 2012 | ($0.20) | ($0.21) | | | View | N/A | |
| 11/9/2012 | Q312 | | $0.07 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for CytRx Corporation (NASDAQ:CYTR)Current Year EPS Consensus Estimate: $-0.5 EPS
Next Year EPS Consensus Estimate: $-0.41 EPS
Dividend History for CytRx Corporation (NASDAQ:CYTR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CytRx Corporation (NASDAQ:CYTR)Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 7.83%
Insider Trades by Quarter for CytRx Corporation (NASDAQ:CYTR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/3/2013 | Scott Bradford Patterson | major shareholder | Buy | 284,979 | $2.44 | $695,348.76 | |
| 11/7/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 50,000 | $2.06 | $103,000.00 | |
| 4/1/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 4,083 | $2.70 | $11,024.10 | |
| 3/20/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 3,980 | $2.61 | $10,387.80 | |
| 3/13/2013 | Scott Bradford Patterson | Major Shareholder | Buy | 55,360 | $2.67 | $147,811.20 | |
| 10/22/2012 | Scott Bradford Patterson | Major Shareholder | Buy | 180,000 | $2.51 | $451,800.00 | |
| 10/18/2012 | Scott Bradford Patterson | Major Shareholder | Buy | 1,200,000 | $2.50 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for CytRx Corporation (NASDAQ:CYTR)
Latest Headlines for CytRx Corporation (NASDAQ:CYTR)
| Source: |
|
CytRx Corporation (CYTR) Chart for Thursday, September, 21, 2017
